Immudex ApS

Immudex ApS specializes in in vitro diagnostic (IVD) kits and reagents focused on T lymphocyte analysis. Their primary product line includes fluorescent-activated cell sorting (FACS) or flow cytometry-based tools, specifically Dextramer reagents. These are designed to detect and measure specific T cell responses, such as those against cytomegalovirus (CMV) and major histocompatibility complex (MHC) antigens. The company’s offerings are tailored for laboratory use in immune monitoring.

Immudex ApS is based in the United States. As a U.S.-based manufacturer, its devices are subject to U.S. regulatory frameworks, including FDA 510(k) submissions and Unique Device Identifier (UDI) listings. This means individual devices undergo evaluation under U.S. regulatory processes, such as the 510(k) pathway for Class I and Class II devices, ensuring compliance with U.S. standards for safety and performance.

Immudex ApS’s devices are listed in the FDA’s 510(k) registry and the UDI (Unique Device Identifier) database. These registries track devices that have undergone FDA review and received regulatory clearance through pathways like the 510(k) premarket notification process. The UDI system ensures traceability and identification of medical devices in commercial distribution, which is critical for post-market surveillance and compliance.

Immudex ApS’s devices are classified as either Class I or Class II under the U.S. FDA regulatory system. Class I devices generally pose minimal risk and may require general controls, while Class II devices involve a higher level of risk and may require special controls to ensure safety and effectiveness. The classification determines the regulatory pathway, such as the 510(k) submission, which ensures these devices meet applicable standards before entering the market.

The Dextramer reagents produced by Immudex ApS are designed for in vitro diagnostic use in flow cytometry or FACS assays. Their purpose is to identify and quantify specific T cell populations by binding to T cell receptors that recognize particular antigens, such as those from cytomegalovirus (CMV) or major histocompatibility complex (MHC) molecules. This helps researchers and clinicians monitor immune responses, particularly in contexts like transplantation or infectious disease management.